Search

Your search keyword '"Vibert, Julien"' showing total 22 results
Start Over Author "Vibert, Julien"
22 results on '"Vibert, Julien"'

1. Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs

Author

Henon, Clémence, Vibert, Julien, Eychenne, Thomas, Gruel, Nadège, Colmet-Daage, Léo, Ngo, Carine, Garrido, Marlène, Dorvault, Nicolas, Marques Da Costa, Maria Eugenia, Marty, Virginie, Signolle, Nicolas, Marchais, Antonin, Herbel, Noé, Kawai-Kawachi, Asuka, Lenormand, Madison, Astier, Clémence, Chabanon, Roman, Verret, Benjamin, Bahleda, Rastislav, Le Cesne, Axel, Mechta-Grigoriou, Fatima, Faron, Matthieu, Honoré, Charles, Delattre, Olivier, Waterfall, Joshua J., Watson, Sarah, and Postel-Vinay, Sophie

Published
2024
Full Text
View/download PDF

3. 782-G The correlation of tumor immune microenvironment with response to neoadjuvant chemotherapy response in undifferentiated pleiomorphic sarcomas: an analysis of the NEOSARCOMICS study

Author

Vibert, Julien, primary, Guégan, Jean-Philippe, additional, Vanhersecke, Lucile, additional, Coindre, Jean-Michel, additional, Toulmonde, Maud, additional, Spalato-Ceruso, Mariella, additional, Peyraud, Florent, additional, Bessede, Alban, additional, and Italiano, Antoine, additional

Published
2023
Full Text
View/download PDF

5. Supplementary Figure S5 from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy

Author

Belkouchi, Younes, primary, Talbot, Hugues, primary, Lassau, Nathalie, primary, Lawrance, Littisha, primary, Farhane, Siham, primary, Feki-Mkaouar, Rahma, primary, Hadchiti, Joya, primary, Dawi, Lama, primary, Vibert, Julien, primary, Cournède, Paul-Henry, primary, Cousteix, Clara, primary, Mazza, Camille, primary, Kind, Michele, primary, Italiano, Antoine, primary, Marabelle, Aurelien, primary, Ammari, Samy, primary, and Champiat, Stephane, primary

Published
2023
Full Text
View/download PDF

6. Data from Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy

Author

Belkouchi, Younes, primary, Talbot, Hugues, primary, Lassau, Nathalie, primary, Lawrance, Littisha, primary, Farhane, Siham, primary, Feki-Mkaouar, Rahma, primary, Hadchiti, Joya, primary, Dawi, Lama, primary, Vibert, Julien, primary, Cournède, Paul-Henry, primary, Cousteix, Clara, primary, Mazza, Camille, primary, Kind, Michele, primary, Italiano, Antoine, primary, Marabelle, Aurelien, primary, Ammari, Samy, primary, and Champiat, Stephane, primary

Published
2023
Full Text
View/download PDF

7. Abstract 96: Integrated molecular analysis of human dedifferentiated liposarcoma identifies a population of liposarcoma progenitors vulnerable to TGF beta inhibition

Author

Gruel, Nadège, primary, Quignot, Chloé, additional, Vibert, Julien, additional, Bonvalot, Sylvie, additional, Zein, Sophie El, additional, Tzanis, Dimitri, additional, Baulande, Sylvain, additional, Mariani, Odette, additional, Waterfall, Joshua, additional, Delattre, Olivier, additional, and Watson, Sarah, additional

Published
2023
Full Text
View/download PDF

8. Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy

Author

Belkouchi, Younes, primary, Talbot, Hugues, additional, Lassau, Nathalie, additional, Lawrance, Littisha, additional, Farhane, Siham, additional, Feki-Mkaouar, Rahma, additional, Hadchiti, Joya, additional, Dawi, Lama, additional, Vibert, Julien, additional, Cournède, Paul-Henry, additional, Cousteix, Clara, additional, Mazza, Camille, additional, Kind, Michele, additional, Italiano, Antoine, additional, Marabelle, Aurelien, additional, Ammari, Samy, additional, and Champiat, Stephane, additional

Published
2023
Full Text
View/download PDF

10. A novel fusion variantLSM14A :: NR4A3in extraskeletal myxoid chondrosarcoma

Author

Ngo, Carine, primary, Verret, Benjamin, additional, Vibert, Julien, additional, Cotteret, Sophie, additional, Levy, Antonin, additional, Pechoux, Cécile Le, additional, Haddag‐Miliani, Leila, additional, Honore, Charles, additional, Faron, Matthieu, additional, Quinquis, Fabien, additional, Cesne, Axel Le, additional, Scoazec, Jean‐Yves, additional, and Pierron, Gaëlle, additional

Published
2022
Full Text
View/download PDF

11. Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions

Author

Vibert, Julien, primary, Saulnier, Olivier, additional, Collin, Céline, additional, Petit, Floriane, additional, Borgman, Kyra J.E., additional, Vigneau, Jérômine, additional, Gautier, Maud, additional, Zaidi, Sakina, additional, Pierron, Gaëlle, additional, Watson, Sarah, additional, Gruel, Nadège, additional, Hénon, Clémence, additional, Postel-Vinay, Sophie, additional, Deloger, Marc, additional, Raynal, Virginie, additional, Baulande, Sylvain, additional, Laud-Duval, Karine, additional, Hill, Véronique, additional, Grossetête, Sandrine, additional, Dingli, Florent, additional, Loew, Damarys, additional, Torrejon, Jacob, additional, Ayrault, Olivier, additional, Orth, Martin F., additional, Grünewald, Thomas G.P., additional, Surdez, Didier, additional, Coulon, Antoine, additional, Waterfall, Joshua J., additional, and Delattre, Olivier, additional

Published
2022
Full Text
View/download PDF

12. ETMR-03. Intra- and extra-cranial BCOR-ITD tumours are separate entities within the BCOR-rearranged family

Author

Bouchoucha, Yassine, primary, Tauziède-Espariat, Arnault, additional, Gauthier, Arnaud, additional, Guillemot, Delphine, additional, Bochaton, Dorian, additional, Vibert, Julien, additional, Carton, Matthieur, additional, Watson, Sarah, additional, Grossetete, Sandrine, additional, Quignot, Chloé, additional, Orbach, Daniel, additional, Corradini, Nadège, additional, Schleiermacher, Gudrun, additional, Bourdeaut, Franck, additional, Simbozel, Marie, additional, Dufour, Christelle, additional, Minard, Veronique, additional, Brahmi, Mehdi, additional, Tirode, Franck, additional, Pissaloux, Daniel, additional, Karanian, Marie, additional, Machet, Marie-Christine, additional, Masliah-Planchon, Julien, additional, Delattre, Olivier, additional, Cardoen, Liesbeth, additional, Pierron, Gaelle, additional, and Doz, Francois, additional

Published
2022
Full Text
View/download PDF

15. Intra‐ and extra‐cranialBCOR‐ ITDtumours are separate entities within theBCOR‐rearranged family

Author

Bouchoucha, Yassine, primary, Tauziède‐Espariat, Arnault, additional, Gauthier, Arnaud, additional, Guillemot, Delphine, additional, Bochaton, Dorian, additional, Vibert, Julien, additional, Carton, Matthieu, additional, Watson, Sarah, additional, Grossetête, Sandrine, additional, Quignot, Chloé, additional, Orbach, Daniel, additional, Corradini, Nadège, additional, Schleiermacher, Gudrun, additional, Bourdeaut, Franck, additional, Simbozel, Marie, additional, Dufour, Christelle, additional, Minard‐Colin, Véronique, additional, Brahmi, Mehdi, additional, Tirode, Franck, additional, Pissaloux, Daniel, additional, Karanian, Marie, additional, Machet, Marie‐Christine, additional, Masliah‐Planchon, Julien, additional, Delattre, Olivier, additional, Cardoen, Liesbeth, additional, Pierron, Gaëlle, additional, and Doz, François, additional

Published
2022
Full Text
View/download PDF

16. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics)

Author

Vibert, Julien, primary, Pierron, Gaëlle, additional, Benoist, Camille, additional, Gruel, Nadège, additional, Guillemot, Delphine, additional, Vincent-Salomon, Anne, additional, Le Tourneau, Christophe, additional, Livartowski, Alain, additional, Mariani, Odette, additional, Baulande, Sylvain, additional, Bidard, François-Clément, additional, Delattre, Olivier, additional, Waterfall, Joshua J., additional, and Watson, Sarah, additional

Published
2021
Full Text
View/download PDF

17. Intra‐ and extra‐cranial BCOR‐ITD tumours are separate entities within the BCOR‐rearranged family.

Author

Bouchoucha, Yassine, Tauziède‐Espariat, Arnault, Gauthier, Arnaud, Guillemot, Delphine, Bochaton, Dorian, Vibert, Julien, Carton, Matthieu, Watson, Sarah, Grossetête, Sandrine, Quignot, Chloé, Orbach, Daniel, Corradini, Nadège, Schleiermacher, Gudrun, Bourdeaut, Franck, Simbozel, Marie, Dufour, Christelle, Minard‐Colin, Véronique, Brahmi, Mehdi, Tirode, Franck, and Pissaloux, Daniel

Subjects
PROGRESSION-free survival, ENDOMETRIUM, TUMORS, CENTRAL nervous system, DNA methylation, OVERALL survival, DNA sequencing
Abstract

BCOR‐ITD tumours form an emerging family of aggressive entities with an internal tandem duplication (ITD) in the last exon of the BCOR gene. The family includes cerebral tumours, termed central nervous system BCOR‐ITD (CNS BCOR‐ITD), and sarcomatous types described in the kidney as clear cell sarcoma of the kidney (CCSK), in the endometrium as high‐grade endometrial stromal sarcoma, and in the bone and soft tissue as undifferentiated round cell sarcoma or primitive myxoid mesenchymal tumour of infancy. Based on a series of 33 retrospective cases, including 10 CNS BCOR‐ITD and 23 BCOR‐ITD sarcomas, we interrogated the homogeneity of the entity regarding clinical, radiological, and histopathological findings, and molecular signatures. Whole‐transcriptomic sequencing and DNA methylation profiling were used for unsupervised clustering. BCOR‐ITD tumours mostly affected young children with a median age at diagnosis of 2.1 years (range 0–62.4). Median overall survival was 3.9 years and progression‐free survival was 1.4 years. This dismal prognosis is shared among tumours in all locations except CCSK. Histopathological review revealed marked differences between CNS BCOR‐ITD and BCOR‐ITD sarcomas. These two groups were consistently segregated by unsupervised clustering of expression (n = 22) and DNA methylation (n = 21) data. Proximity between the two groups may result from common somatic changes within key pathways directly related to the novel activity of the ITD itself. Conversely, comparison of gene signatures with single‐cell RNA‐Seq atlases suggests that the distinction between BCOR‐ITD sarcomas and CNS BCOR‐ITD may result from differences in cells of origin. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

Author

Benjamin Davido, Nicolas Simon, Jean-Claude Alvarez, Isabelle Etting, P Moine, Djillali Annane, Islam Amine Larabi, Dupuis, Christine, Infection et inflammation (2I), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Raymond Poincaré [AP-HP], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pharmacologie Clinique [AP-HM Hôpital Ste Marguerite], Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Garches COVID-19 Collaborative Group*Ambrosi, Xavier, Amthor, Suzanne, Bounab, Rania, Chentouh, Ryme, Clair, Bernard, Fayssoil, Abdallah, Friedman, Diane, Heming, Nicholas, Maxime, Virginie, Niel Duriez, Myriam, Orlikowski, David, Santi, Francesca, Villart, Maryvonne, Michelon Hugues, Abbar, Baptiste, Dray, Juliah, Tamayo, Juan, Pascault, Alice, Zini, and Justine, Bennington, Steven, Moucachen, Myriam, Gay, Pierre, Luxman, Majistor, Kochbati, Elias, Martinez, Valéria, Guichard, Léa, Trabelsi, Chawki, Boutros, Marie, Schitter, Sebastien, Meuleye, Simone, Reysz, Suzanne, Khiter, Hakim, Dosne Blachier, Brigitte, Bron, Anne Lyse, Defouchecour, Etiennette, Hamon Pietrin, Damien, Coester, Denys, Bergounioux Jean, Omar, Amal, Guillon, Maud, Amthor, Helge, Prigent, Helene, Lofaso, Frédéric, Denys Pierre, Bensmail, Djamel, Joussain, Charles, Malot, Claire, Lansaman, Thibaut, Leotard, Antoine, Le Liepvre, Hélène, Rech, Celia, Paquereau, Julie, Kagane, Lauren, Levy, Jonathan, Chkron, Elsa, Angioni, Florence, Karabulut, Céline, Lemoine, Jérôme, Vibert, Julien, Trystram, Noémie, Christian Perronne, Véronique Perronne, Aurélien Dinh, Pierre de Truchis, Soline Simeon, Bessis Simon, Morgan Matt, Hélène Mascitti, Stéphanie Landowski, Pascal Crenn, Aurélie Le Gal, Aymeric Lanore, Julia Nguyen Van Thang, Louis Jacob, Nicolas Kiavue, Marc Hobeika, Jean Louis Gaillard, Jean Louis Hermann, Martin Rottman, Anne Laure Roux, Marie-Anne Welti, Elyanne Gault, Christine Lawrence.

Subjects
medicine.medical_specialty, [SDV]Life Sciences [q-bio], Population, Cmax, Lopinavir/ritonavir, 030226 pharmacology & pharmacy, Gastroenterology, Lopinavir, 03 medical and health sciences, Cmin, 0302 clinical medicine, Pharmacokinetics, immune system diseases, Internal medicine, medicine, Pharmacology (medical), 030212 general & internal medicine, education, Pharmacology, education.field_of_study, business.industry, virus diseases, General Medicine, Pharmacokinetics and Disposition, 3. Good health, NONMEM, [SDV] Life Sciences [q-bio], Ritonavir, business, Covid-19, medicine.drug
Abstract

Objective To develop a population pharmacokinetic model for lopinavir boosted by ritonavir in coronavirus disease 2019 (Covid-19) patients. Methods Concentrations of lopinavir/ritonavir were assayed by an accredited LC-MS/MS method. The population pharmacokinetics of lopinavir was described using non-linear mixed-effects modeling (NONMEM version 7.4). After determination of the base model that better described the data set, the influence of covariates (age, body weight, height, body mass index (BMI), gender, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), C reactive protein (CRP), and trough ritonavir concentrations) was tested on the model. Results From 13 hospitalized patients (4 females, 9 males, age = 64 ± 16 years), 70 lopinavir/ritonavir plasma concentrations were available for analysis. The data were best described by a one-compartment model with a first-order input (KA). Among the covariates tested on the PK parameters, only the ritonavir trough concentrations had a significant effect on CL/F and improved the fit. Model-based simulations with the final parameter estimates under a regimen lopinavir/ritonavir 400/100 mg b.i.d. showed a high variability with median concentration between 20 and 30 mg/L (Cmin/Cmax) and the 90% prediction intervals within the range 1–100 mg/L. Conclusion According to the estimated 50% effective concentration of lopinavir against SARS-CoV-2 virus in Vero E6 cells (16.7 mg/L), our model showed that at steady state, a dose of 400 mg b.i.d. led to 40% of patients below the minimum effective concentration while a dose of 1200 mg b.i.d. will reduce this proportion to 22%. Electronic supplementary material The online version of this article (10.1007/s00228-020-03020-w) contains supplementary material, which is available to authorized users.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results